HIGHLIGHTS
- who: Michael Craven et al. from the leads to a post-treatment reduction in real world distress and avoidance for patients with psychosis attending NHS mental health servicesTreatment as usual will be measured but remain unchanged in both groups. Assessments will be carried out at , (baseline), (post-treatment) and , (follow-up) weeks by a researcher blind to treatment allocation. A summary of the trial design can be seen in figure, . The trial is prospectively registered with the ISRCTN registry: ISRCTN17308399. There is a Data Monitoring and Ethics Committee. Randomisation, blinding and code-breaking Participants will be randomised . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.